Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Average Rating of “Moderate Buy” by Analysts

Mersana Therapeutics, Inc. (NASDAQ:MRSN) has been given a consensus recommendation of “Moderate Buy” by the nine research firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $5.57.

MRSN has been the subject of a number of recent research reports. Wedbush restated an “outperform” rating and set a $4.00 price objective (down from $7.00) on shares of Mersana Therapeutics in a research note on Friday, January 10th. Citigroup initiated coverage on Mersana Therapeutics in a research note on Friday, November 15th. They set a “buy” rating and a $5.00 price objective for the company. Finally, William Blair started coverage on Mersana Therapeutics in a research note on Thursday, February 6th. They set an “outperform” rating for the company.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Mackenzie Financial Corp bought a new position in Mersana Therapeutics during the fourth quarter valued at about $131,000. Sphera Funds Management LTD. bought a new position in Mersana Therapeutics during the fourth quarter valued at about $987,000. Nuveen Asset Management LLC boosted its stake in Mersana Therapeutics by 53.6% during the fourth quarter. Nuveen Asset Management LLC now owns 232,223 shares of the company’s stock valued at $332,000 after buying an additional 81,022 shares in the last quarter. Millennium Management LLC boosted its stake in Mersana Therapeutics by 206.4% during the fourth quarter. Millennium Management LLC now owns 795,973 shares of the company’s stock valued at $1,138,000 after buying an additional 536,190 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its stake in Mersana Therapeutics by 12.0% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,111,998 shares of the company’s stock valued at $1,590,000 after buying an additional 118,952 shares in the last quarter. Institutional investors own 93.92% of the company’s stock.

Mersana Therapeutics Price Performance

Shares of MRSN opened at $0.53 on Friday. The company has a market cap of $65.87 million, a P/E ratio of -0.87 and a beta of 1.39. The stock has a fifty day moving average price of $0.97 and a 200 day moving average price of $1.60. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35. Mersana Therapeutics has a 12 month low of $0.49 and a 12 month high of $6.28.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.